Tarride Jean-Eric, Prajapati Vimal H, Lynde Charles, Blackhouse Gord
Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada.
Programs for Assessment of Technology in Health (PATH), The Research Institute of St. Joe's Hamilton, St. Joseph's Healthcare, Hamilton, Canada.
JAAD Int. 2023 Apr 15;12:151-159. doi: 10.1016/j.jdin.2023.04.002. eCollection 2023 Sep.
Not much is known about the burden of palmoplantar pustulosis (PPP).
To document the burden of PPP in Canada, and to compare with psoriasis vulgaris (PV).
Adult Canadians (excluding the province of Quebec) hospitalized or visiting an emergency department (ED) or hospital-/community-based clinic between April 1, 2007, and March 31, 2020, with a diagnostic code indicating PPP (ICD-10-CA: L40.3) or PV (ICD10-CA: L40.9 or L40.0) were identified using Canadian administrative data. 10-year prevalent- and 3-year incident-based approaches were conducted. Costs were determined when the most responsible diagnosis (MRD) for the admission was PPP or PV (MRD costs) and for all reasons (all-cause costs).
In the prevalence analysis, the 10-year mean (standard deviation [SD]) and MRD costs were $544 ($1874) for PPP and $222 ($1828) for PV ( < .01). In the incidence analysis, PPP patients had higher 3-year mean (SD) MRD costs ($1078 [$2705]) than PV ($503 [$2267]) ( < .01). All-cause costs were lower for the PPP cohort in the prevalent and incident analyses. There were no differences in all-cause inpatient mortality between PPP and PV.
Physician and prescription data were not available.
PPP patients incurred significantly higher MRD costs than PV patients.
关于掌跖脓疱病（PPP）的负担了解不多。
记录加拿大PPP的负担，并与寻常型银屑病（PV）进行比较。
利用加拿大行政数据识别2007年4月1日至2020年3月31日期间住院或前往急诊科（ED）或医院/社区诊所就诊的成年加拿大人（不包括魁北克省），其诊断代码表明患有PPP（国际疾病分类第十版加拿大修订本：L40.3）或PV（国际疾病分类第十版加拿大修订本：L40.9或L40.0）。采用了基于10年患病率和3年发病率的方法。当入院的最主要诊断（MRD）为PPP或PV（MRD成本）以及所有原因（全因成本）时确定成本。
在患病率分析中，PPP的10年平均（标准差[SD]）和MRD成本为544美元（1874美元），PV为222美元（1828美元）（P<0.01）。在发病率分析中，PPP患者的3年平均（SD）MRD成本（1078美元[2705美元]）高于PV患者（503美元[2267美元]）（P<0.01）。在患病率和发病率分析中，PPP队列的全因成本较低。PPP和PV之间的全因住院死亡率没有差异。
没有医生和处方数据。
PPP患者的MRD成本显著高于PV患者。
